Engene Holdings Inc. (ENGN)
NASDAQ:ENGN
Want to see ENGN full AI Analyst Report?
Top Page
enGene Holdings
(NASDAQ:ENGN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-75.22% Downside)
Action:Reiterated
Date:05/15/26
Overall score reflects weak financial performance (no revenue, heavy cash burn) and bearish technicals (price well below moving averages with negative momentum). A relatively strong balance sheet and a positive corporate update tied to a commercialization push provide partial support, but valuation is not compelling due to losses and no dividend.
Positive Factors
Strong balance sheet, low leverage
Material equity and minimal debt provide durable financial flexibility to fund late-stage trials and CMC work without immediate revenue. This reduces near-term default risk and gives management capacity to execute regulatory and commercialization steps before significant external financing is required.
Negative Factors
Persistent negative operating cash flow
Deep, sustained cash burn creates a durable funding requirement that can force dilution or debt raising before commercial revenues arrive. High ongoing cash needs limit optionality for R&D expansion or marketing investments and increase execution risk through 2-6 months and beyond.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet, low leverage
Material equity and minimal debt provide durable financial flexibility to fund late-stage trials and CMC work without immediate revenue. This reduces near-term default risk and gives management capacity to execute regulatory and commercialization steps before significant external financing is required.
Read all positive factors
enGene Holdings (ENGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$117.90M
Dividend YieldN/A
Average Volume (3M)2.66M
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue GrowthN/A
EPS Growth-48.08%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.24
Shares Outstanding66,989,460
10 Day Avg. Volume3,047,796
30 Day Avg. Volume2,660,213
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-427.57
Enterprise Value/Ebitda-0.68
Forecast
1Y Price Target
$6.86Price Target Upside-15.03% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.97
Revenue Forecast (FY)N/A
enGene Holdings Business Overview & Revenue Model
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is E...
How the Company Makes Money
null...
enGene Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -189.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -118.89M | -113.80M | -52.04M | -94.77M | -22.78M | -18.14M |
| Net Income | -122.44M | -117.30M | -55.14M | -99.92M | -24.46M | -23.44M |
Balance Sheet | ||||||
| Total Assets | 337.11M | 221.47M | 311.17M | 86.96M | 132.04M | 131.45M |
| Cash, Cash Equivalents and Short-Term Investments | 275.95M | 193.81M | 238.40M | 81.60M | 314.15K | 1.07M |
| Total Debt | 33.46M | 31.80M | 25.02M | 9.78M | 0.00 | 0.00 |
| Total Liabilities | 55.57M | 53.76M | 38.56M | 14.47M | 4.62M | 4.05M |
| Stockholders Equity | 281.55M | 167.71M | 272.61M | 72.49M | 127.42M | 127.39M |
Cash Flow | ||||||
| Free Cash Flow | -103.78M | -100.72M | -49.21M | -25.06M | -17.75M | -16.23M |
| Operating Cash Flow | -102.45M | -99.24M | -48.28M | -24.74M | -17.59M | -15.98M |
| Investing Cash Flow | -66.47M | -25.14M | -125.95M | -318.00K | -153.00K | -247.00K |
| Financing Cash Flow | 143.18M | 1.52M | 265.72M | 86.15M | 27.97M | 22.52M |
enGene Holdings Technical Analysis
Negative
8.07
Price Trends
5.80
Negative
7.56
Negative
7.29
Negative
Market Momentum
-1.46
Negative
27.75
Positive
70.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENGN, the sentiment is Negative. The current price of 8.07 is above the 20-day moving average (MA) of 3.43, above the 50-day MA of 5.80, and above the 200-day MA of 7.29, indicating a bearish trend. The MACD of -1.46 indicates Negative momentum. The RSI at 27.75 is Positive, neither overbought nor oversold. The STOCH value of 70.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENGN.
enGene Holdings Risk Analysis
enGene Holdings disclosed 84 risk factors in its most recent earnings report. enGene Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
enGene Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $512.19M | -8.43 | -27.09% | ― | ― | -1.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.70B | -12.86 | -59.27% | ― | -100.00% | -62.96% | |
49 Neutral | $32.27M | -1.10 | -64.17% | ― | -100.00% | 94.65% | |
46 Neutral | $340.95M | -4.31 | -0.11% | ― | ― | 40.79% | |
45 Neutral | $117.90M | -5.39 | -55.83% | ― | ― | -48.08% | |
43 Neutral | $379.83M | -3.16 | -102.69% | ― | ― | -13.96% |
* Healthcare Sector Average
ENGN
enGene Holdings
1.72
-2.27
-56.89%
TVRD
Tvardi Therapeutics
3.30
-27.56
-89.31%
CAPR
Capricor Therapeutics
29.14
18.49
173.62%
REPL
Replimune Group
4.70
-3.73
-44.25%
IMRX
Immuneering
5.34
3.54
196.39%
CTNM
Contineum Therapeutics, Inc. Class A
13.44
10.04
295.29%
enGene Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
enGene Releases Mixed Interim Data from LEGEND Phase 2 Trial
Neutral
May 7, 2026
On May 5, 2026, enGene USA amended and restated the employment agreement with Dr. Hussein Sweiti, effective May 6, 2026, updating his compensation to a $561,750 base salary, a 40% annual bonus opportunity, and continued benefit eligibility. The ne...
Business Operations and StrategyRegulatory Filings and Compliance
enGene Therapeutics Rebrands as Company Nears Commercialization
Positive
Apr 9, 2026
enGene Therapeutics Inc., a clinical-stage, non-viral genetic medicines company focused on high-need diseases such as non-muscle invasive bladder cancer, is advancing its lead gene therapy candidate detalimogene voraplasmid through the Phase 2 LEG...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.